colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate
COLY-MYCIN S (colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate) by Pfizer is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics. First approved in 1962.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
COLY-MYCIN S is a fixed-dose otic suspension combining two antibiotics (colistin sulfate and neomycin sulfate) with a corticosteroid (hydrocortisone acetate) and a surfactant (thonzonium bromide). It treats superficial bacterial infections of the external auditory canal caused by susceptible gram-positive and gram-negative organisms. The antibiotics disrupt bacterial cell membranes and protein synthesis while the corticosteroid reduces inflammation and edema.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on retention and cost management rather than growth initiatives.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on COLY-MYCIN S at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on COLY-MYCIN S offers stability in a commodity market but limited growth trajectory; roles are primarily defensive, focused on market share retention and cost management. Career advancement typically requires transition to growth-stage products or specialty indications.